These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24290212)

  • 21. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
    Crombet O; Lastrapes K; Zieske A; Morales-Arias J
    Pediatr Blood Cancer; 2012 Aug; 59(2):333-4. PubMed ID: 22689211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
    Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
    Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
    Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
    Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abdominal pain in a patient with acute lymphoblastic leukaemia.
    Breitenstein A; Kühne R; Minder EI; Marek A; Goede J; Schanz U; Renner C
    Ann Hematol; 2010 Feb; 89(2):211-2. PubMed ID: 19588138
    [No Abstract]   [Full Text] [Related]  

  • 28. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
    Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
    Willemze R; Labar B
    Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
    Giebel S; Labopin M; Gorin NC; Caillot D; Leguay T; Schaap N; Michallet M; Dombret H; Mohty M
    Eur J Cancer; 2014 Jan; 50(2):411-7. PubMed ID: 24210524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adult ALL: where are we and where are we going?
    Larson RA
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):342-4. PubMed ID: 16163203
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib (Sprycel) for CML and Ph + ALL.
    Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.
    Mattison RJ; Larson RA
    Curr Opin Oncol; 2009 Nov; 21(6):601-8. PubMed ID: 19713843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
    Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review.
    Oliansky DM; Camitta B; Gaynon P; Nieder ML; Parsons SK; Pulsipher MA; Dillon H; Ratko TA; Wall D; McCarthy PL; Hahn T;
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):505-22. PubMed ID: 22209888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    de Castro CG; Gregianin LJ; Meneses CF; Brunetto AL
    Pediatr Blood Cancer; 2009 Dec; 53(6):1161. PubMed ID: 19621456
    [No Abstract]   [Full Text] [Related]  

  • 40. Dasatinib.
    Kantarjian H; Jabbour E; Grimley J; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Sep; 5(9):717-8. PubMed ID: 17001803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.